¹ú²úÂ鶹¾«Æ·

December 17, 2024 | 11:00 am EST

Respiratory syncytial virus (RSV) is the leading cause of pneumonia and bronchiolitis in infants, as well as hospitalisations and deaths in the first months of life. Currently, there are no specific treatments for RSV infection, making supportive measures the main line of therapy. Among the preventive measures, maternal vaccination aims to prevent RSV-associated disease in infants during the first six months through the transfer of antibodies during gestation. The ¹ú²úÂ鶹¾«Æ· Technical Advisory Group has issued recommendations on the use of this vaccine in the Americas, and ¹ú²úÂ鶹¾«Æ· has published an annex to the Field Guide on Maternal and Neonatal Immunisation for Latin America and the Caribbean, specific to maternal RSV vaccination. 

Objective:

To disseminate relevant information on the maternal RSV vaccine based on prefusion protein F (RSVpreF) for the prevention of RSV-associated complications in infants, including the annex to the Field Guide, ¹ú²úÂ鶹¾«Æ· Advisory Group recommendations and considerations for implementation.

Target audience

Representatives from national and sub-national Ministries of Health, immunisation, maternal and newborn health programme managers, health facility and programme managers, non-governmental organisations, professional associations with expertise in maternal and newborn care, health professionals involved in antenatal care, researchers, community representatives and users.

AGENDA

Simultaneous interpretation will be provided in Spanish and English.

.